New York State Common Retirement Fund Sells 584 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

New York State Common Retirement Fund lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,619 shares of the company’s stock after selling 584 shares during the quarter. New York State Common Retirement Fund owned 0.11% of Medpace worth $8,623,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Liberty Wealth Management LLC lifted its holdings in Medpace by 67.1% during the 3rd quarter. Liberty Wealth Management LLC now owns 137 shares of the company’s stock valued at $28,000 after buying an additional 55 shares in the last quarter. USA Financial Portformulas Corp purchased a new stake in Medpace during the 3rd quarter worth approximately $62,000. Clearstead Advisors LLC grew its position in Medpace by 126.0% during the 3rd quarter. Clearstead Advisors LLC now owns 339 shares of the company’s stock worth $64,000 after purchasing an additional 189 shares during the last quarter. Stephens Inc. AR purchased a new stake in Medpace during the 3rd quarter worth approximately $77,000. Finally, Marshall Wace LLP acquired a new stake in Medpace during the 1st quarter valued at approximately $99,000. Hedge funds and other institutional investors own 96.88% of the company’s stock.

Shares of MEDP opened at $150.62 on Friday. Medpace Holdings, Inc. has a 12-month low of $136.80 and a 12-month high of $231.00. The firm has a 50-day moving average price of $154.84 and a 200 day moving average price of $184.55. The firm has a market capitalization of $5.07 billion, a P/E ratio of 31.31 and a beta of 1.48.

Medpace (NASDAQ:MEDPGet Rating) last announced its quarterly earnings data on Sunday, February 13th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.07. Medpace had a net margin of 15.92% and a return on equity of 20.55%. The firm had revenue of $308.55 million during the quarter, compared to analyst estimates of $309.03 million. During the same quarter in the prior year, the firm posted $1.39 earnings per share. Medpace’s quarterly revenue was up 18.8% on a year-over-year basis. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 5.57 EPS for the current year.

MEDP has been the subject of several analyst reports. Zacks Investment Research cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, February 19th. began coverage on shares of Medpace in a report on Thursday, March 31st. They issued a “buy” rating for the company. Finally, Robert W. Baird upped their target price on shares of Medpace from $160.00 to $175.00 in a report on Thursday, March 17th.

Medpace Profile (Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More

Want to see what other hedge funds are holding MEDP? Visit to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with's FREE daily email newsletter.